checkAd

    DGAP-News  595  0 Kommentare Achievement of multiple milestones in Evotec's drug discovery alliances - Seite 2


    Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen
    Pharmaceuticals in the field of depression and with Roche in the field of
    Alzheimer's disease. For additional information please go to
    www.evotec.com.


    FORWARD LOOKING STATEMENTS - Information set forth in this press release
    contains forward-looking statements, which involve a number of risks and
    uncertainties. The forward-looking statements contained herein represent
    the judgement of Evotec as of the date of this press release. Such
    forward-looking statements are neither promises nor guarantees, but are
    subject to a variety of risks and uncertainties, many of which are beyond
    our control, and which could cause actual results to differ materially from
    those contemplated in these forward-looking statements. We expressly
    disclaim any obligation or undertaking to release publicly any updates or
    revisions to any such statements to reflect any change in our expectations
    or any change in events, conditions or circumstances on which any such
    statement is based.


    Contact Evotec AG:
    Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
    +49.(0)40.56081-255, gabriele.hansen@evotec.com



    ---------------------------------------------------------------------

    18.12.2014 Dissemination of a Corporate News, transmitted by DGAP - a
    service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements,
    Financial/Corporate News and Press Releases.
    Media archive at www.dgap-medientreff.de and www.dgap.de

    ---------------------------------------------------------------------


    Language: English
    Company: Evotec AG
    Manfred Eigen Campus / Essener Bogen 7
    22419 Hamburg
    Germany
    Phone: +49 (0)40 560 81-0
    Fax: +49 (0)40 560 81-222
    E-mail: info@evotec.com
    Internet: www.evotec.com
    ISIN: DE0005664809
    WKN: 566480
    Indices: TecDAX
    Listed: Regulierter Markt in Frankfurt (Prime Standard);
    Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
    München, Stuttgart


    End of News DGAP News-Service
    ---------------------------------------------------------------------
    307261 18.12.2014
    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Achievement of multiple milestones in Evotec's drug discovery alliances - Seite 2 DGAP-News: Evotec AG / Key word(s): Miscellaneous Achievement of multiple milestones in Evotec's drug discovery alliances 18.12.2014 / 17:30 --------------------------------------------------------------------- Hamburg, Germany - 18 December 2014: …

    Schreibe Deinen Kommentar

    Disclaimer